Factors impacting on prognosis and treatment in patients with liver and lung metastases from colorectal cancer

Submission date	Recruitment status	Prospectively registered
29/11/2017	No longer recruiting	☐ Protocol
Registration date	Overall study status	Statistical analysis plan
22/01/2018	Completed	Results
Last Edited	Condition category	Individual participant data
14/06/2019	Cancer	[] Record updated in last year

Plain English summary of protocol

Background and study aims

Colorectal cancer means cancer that starts in the colon (large bowel) or back passage (rectum). It is a common cancer, and in about half of patients it will spread to the liver (liver metastases). For patients with liver metastases the only treatment with long-term survival is surgery. It is however less well studied as to how many of those patients will also develop lung metastases, and above all which treatment will be the most beneficial. The aim of this study is to find out whether lung surgery improves survival, compared to chemotherapy, for patients with liver and lung metastases from colorectal cancer.

Who can participate?

All patients with liver and lung metastases from colorectal cancer

What does the study involve?

Data is gathered from the Swedish Colorectal Cancer Registry from 2007 to 2016, from the Swedish Liver Registry from 2008 to 2016 and from the Swedish Thoracic Registry from 2009 to 2016. Data is also gathered from the In Patients Registry and from the Death Registry from 2007 to 2016. The study period is from 2007 to 2016. From these registries all patients with liver and lung metastases from colorectal cancer are identified. The main study questions is whether there is any difference in survival depending on the type of treatment for liver and lung metastases and if there is any factor that may affect survival. The aim is to find out whether liver and lung surgery for patients with colorectal cancer results in an improved survival compared to liver surgery and palliative chemotherapy for lung metastases.

What are the possible benefits and risks of participating? There are no benefits or risks for participants as the study only uses data gathered from registries.

Where is the study run from?

- 1. Linköping University Hospital (Sweden)
- 2. Lund University Hospital (Sweden)

- 3. Karolinska University Hospital (Sweden)
- 4. Uppsala University Hospital (Sweden)
- 5. Umeå University Hospital (Sweden)
- 6. Sahlgrenska University Hospital (Sweden)

When is the study starting and how long is it expected to run for? June 2017 to June 2020

Who is funding the study? Linköping University Hospital

Who is the main contact? Dr Kristina Hasselgren Kristina.Hasselgren@liu.se

Contact information

Type(s)

Scientific

Contact name

Dr Kristina Hasselgren

ORCID ID

https://orcid.org/0000-0002-0792-1588

Contact details

Linköping University Hospital Garnisonsvägen Linköping Sweden 581 85 +46 (0)10 1030000 Kristina.Hasselgren@liu.se

Additional identifiers

Protocol serial number

N/A

Study information

Scientific Title

Factors impacting on prognosis and treatment in patients with liver and lung metastases from colorectal cancer - a Swedish national study

Study objectives

The aim of the study is to evaluate whether patients with liver and lung metastases from colorectal cancer have an improved survival if the are treated with liver and lung surgery compared to liver surgery and palliative chemotherapy for lung metastases.

Ethics approval required

Old ethics approval format

Ethics approval(s)

The Regional Ethical Review Board in Linköping, 09/20/2017, ref 2017/363-31

Study design

The study is a national registry study based on data from the Swedish Colorectal Cancer Registry (SCRCR), The Swedish Liver Registry (Sweliv) and The Swedish Thoracic Registry (ThoR)

Primary study design

Observational

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Patients with liver and lung metastases from colorectal cancer

Interventions

Data will be gathered from the Swedish Colorectal Cancer Registry from 2007 to 2016, from the Swedish Liver Registry from 2008 to 2016 and from the Swedish Thoracic Registry from 2009 to 2016. Data will also be gathered from the In Patients Registry and from the Death Registry from 2007 to 2016. The study period will be from 2007 to 2016. From these registries all patients with liver- and lung metastases from colorectal cancer will be identified. The main study questions is whether there is any difference in survival depending on treatment of liver- and lung metastases (resection, ablation, stereotactic body radiation therapy or chemotherapy) and if there is any prognostic factor that may affect the survival. The primary aim is to study whether liver and lung surgery for patients with colorectal cancer results in an improved survival compared to liver surgery and palliative chemotherapy for lung metastases.

Intervention Type

Procedure/Surgery

Primary outcome(s)

Survival estimated from time of the diagnosis of the primary tumor, and for patients with metachronous liver metastases from the diagnosis of the liver metastases

Key secondary outcome(s))

Factors, beside surgery, that have an impact on prognosis and survival

Completion date

30/06/2020

Eligibility

Key inclusion criteria

All patients with liver and lung metastases from colorectal cancer

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

Other diagnoses than colorectal cancer

Date of first enrolment

01/01/2008

Date of final enrolment

31/12/2016

Locations

Countries of recruitment

Sweden

Study participating centre Linköping University Hospital

Linköping Sweden 581 85

Study participating centre Lund University Hospital

Lund Sweden 222 41

Study participating centre Karolinska University Hospital

Stockholm Sweden 171 76

Study participating centre Uppsala University Hospital

Uppsala Sweden 751 85

Study participating centre Umeå University Hospital

Umeå Sweden 907 37

Study participating centre Sahlgrenska University Hospital Gothenburg Sweden 431 80

Sponsor information

Organisation

Region Östergötland

ROR

https://ror.org/0326gsy75

Funder(s)

Funder type

Hospital/treatment centre

Funder Name

Linköping University Hospital

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are/will be available upon request from Per Sandström (per.sandstom@liu.se).

IPD sharing plan summary

Available on request

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?

Participant information sheet
Participant information sheet
11/11/2025 No Yes